Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages ove...
Does This Move Make Merck Stock a Buy?
Merck (MRK -1.91%), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its fa...
Merck & Co.: A Pharma Titan At A Discount
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its c...
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted pri...
Dividend Yield Theory Says Merck Is A Buy
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent exp...
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significan...
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipe...
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention.
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial H...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR...
Related Companies